ID   MCF10A_EZH2_10A3
AC   CVCL_C0ZX
DR   EGA; EGAD00001008559
DR   Wikidata; Q114312240
RX   PubMed=35692635;
CC   Part of: Cancer Pathway Knockout Panel.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; HGNC:3527; EZH2.
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Homozygous (from parent cell line).
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: In situ; Breast, epithelium; UBERON=UBERON_0008367.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0598 ! MCF-10A
SX   Female
AG   36Y
CA   Spontaneously immortalized cell line
DT   Created: 22-09-22; Last updated: 10-04-25; Version: 7
//
RX   PubMed=35692635; DOI=10.1016/j.isci.2022.104437; PMCID=PMC9184558;
RA   Cook, Ashley L.
RA   Wyhs, Nicolas
RA   Sur, Surojit
RA   Ptak, Blair
RA   Popoli, Maria
RA   Dobbyn, Laura
RA   Papadopoulos, Tasos
RA   Bettegowda, Chetan
RA   Papadopoulos, Nickolas
RA   Vogelstein, Bert
RA   Zhou, Shi-Bin
RA   Kinzler, Kenneth Wayne
RT   "An isogenic cell line panel for sequence-based screening of targeted
RT   anticancer drugs.";
RL   iScience 25:104437.1-104437.13(2022).
//